Who Paid My Doc
Pylarify
Drug Radiopharmaceutical
NDC 71258-022-01
General payments
$5,811,585
Research payments
$8,383,495
Through program year 2025, $5,811,585 in general payments and $8,383,495 in research payments were reported against Pylarify (Radiopharmaceutical).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,620,859 | 6,055 |
| 2025 | Research | $3,188,833 | 405 |
| 2024 | General | $1,562,223 | 6,433 |
| 2024 | Research | $1,943,029 | 245 |
| 2023 | General | $1,483,607 | 6,775 |
| 2023 | Research | $592,468 | 95 |
| 2022 | General | $981,839 | 3,834 |
| 2022 | Research | $920,364 | 186 |
| 2021 | General | $159,794 | 744 |
| 2021 | Research | $1,738,800 | 378 |
| 2019 | General | $3,263 | 1 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 72 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
23,842 general · 1,309 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.